SNHG20 down-regulates p21 and E-cadherin in ovarian cancer (177), activates STAT6 in hepatocellular carcinoma (178), represses miR140 in laryngeal squamous cell carcinoma (179), modulates ATM (ataxia telangiectasia mutated)–JAK (janus kinase 2)–PD-L1 (programmed death-ligand 1) pathway in esophageal carcinoma (180), up-regulates TGF-B1 in nasopharyngeal carcinoma (181), and enhances EMT and apoptosis via miR-139 -RUNX2 (runt-related transcription factor 2) in osteosarcoma (182, 183). Here, RUNX2 is linked to ovarian cancer.